Sustainability has become a paramount concern in the biopharma industry, as evidenced by a recent comprehensive survey conducted by Cytiva and the Financial Times research unit, FT Longitude. This survey, involving over 800 executives from diverse global companies, reveals a growing commitment to
Employee turnover in the biopharma industry has reached unprecedented levels in recent years, causing a significant threat to intellectual property (IP) security. As the sector grapples with layoffs and recruitment shifts, there is an increasing need to understand how these workforce changes impact
Regeneron Pharmaceuticals recently hit a roadblock in its quest to bring its experimental multiple myeloma drug, linvoseltamab, to market. Although the drug promises significant benefits to patients, manufacturing flaws at a third-party facility have delayed FDA approval. This analysis delves into
Recent tensions between the United States and China have extended into the biotech and pharmaceutical sectors, sparking bipartisan calls for increased regulatory scrutiny. At the heart of the matter: clinical trials conducted by U.S. pharmaceutical companies in collaboration with Chinese
The second quarter of 2024 marked a significant period for the top 20 biopharmaceutical companies as they navigated improving global markets. Bolstered by investor optimism and anticipated interest rate cuts from the US Federal Reserve, these companies showed robust performances and strategic
Fujifilm Diosynth Biotechnologies has taken a significant step toward bolstering its microbial production capabilities with the inauguration of a new microbial fermentation manufacturing facility in Billingham, UK. As a leading contract development and manufacturing organization (CDMO), the company
AN2 Therapeutics, a prominent biopharmaceutical company, has announced a major restructuring of its operations following an unexpected clinical trial outcome. This decision marks a significant strategic pivot from their previous research initiatives and has substantial implications for the
The biotech industry, much like any other sector, has been significantly impacted by the COVID-19 pandemic. The extraordinary boom in 2020 and 2021 led to an influx of investments and an unprecedented surge in innovations. However, as the world transitions into a post-pandemic era, the biotech
A groundbreaking advancement in tumor immunotherapy is unfolding with the approval of a new mRNA vaccine for Epstein-Barr virus (EBV) positive tumors by China's National Medical Products Administration (NMPA) for Phase-I clinical trials. Developed independently by WestGene Biopharma Co., Ltd.,
In response to a significant decrease in early-stage research spending, Evotec, a leading German company focusing on drug discovery and contract development and manufacturing (CDMO), is undertaking substantial strategic changes. Under the new leadership of CEO Christian Wojczewski, Evotec has
